Meningococcal groups A, B, C, W, and Y vaccine (Penbraya) induces the production of bactericidal antibodies specific to the capsular polysaccharides of Neisseria meningitidis serogroups A, C, W, and Y and to outer membrane protein factor H binding protein subfamily A and B variants of N. meningitidis group B.
Smallpox and mpox vaccine, live, non-replicating (Jynneos) vaccine is a live vaccine produced from the strain Modified Vaccinia Ankara-Bavarian Nordic, an attenuated, non-replicating orthopoxvirus that creates a humoral and cellular immune response to orthopoxviruses.
FDA APPROVALS
On October 20, 2023, FDA approved meningococcal groups A, B, C, W, and Y vaccine (Penbraya) for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y for individuals 10 through 25 years of age.
On September 24, 2019, smallpox and mpox vaccine, live, non-replicating (Jynneos) vaccine is FDA-approved for the prevention of smallpox and mpox disease in adults 18 years of age and older determined to be at high risk for smallpox and mpox infection.
ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) RECOMMENDATIONS
On October 26, 2023, the Advisory Committee on Immunization Practices (ACIP) recommended meningococcal groups A, B, C, W, and Y vaccine (Penbraya) for individuals 16 through 23 years of age when indicated by shared clinical decision-making for Meningococcal B vaccination and for individuals 10 years of age and older at increased risk of meningococcal disease (e.g., due to persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia) due for the MenACWY and MenB vaccine.
On October 26, 2023, the Advisory Committee on Immunization Practices (ACIP) recommended the two-dose Jynneos (smallpox and mpox vaccine, live, non-replicating) vaccine for individuals 18 years and older who are at risk for Mpox.
Meningococcal Vaccine
Meningococcal groups A, B, C, W, and Y vaccine (Penbraya) is considered medically necessary and, therefore, covered as a preventive service for the following individuals:
- Individuals 16 through 23 years of age when indicated by shared clinical decision-making for meningococcal B vaccination.
- Individuals 10 years of age and older at increased risk of meningococcal disease (e.g., due to persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia) due for the MenACWY and MenB vaccine.
Smallpox and Mpox Vaccine
Smallpox and mpox vaccine, live, non-replicating (Jynneos) vaccine is considered medically necessary and, therefore, covered as a preventive service as a two-dose vaccine for individuals 18 years and older who are at risk for Mpox.
According to ACIP, risk factors for Mpox are:
- Gay, bisexual, and other men who have sex with men, transgender or nonbinary individuals who in the past six months had one of the following:
- A new diagnosis of at least one sexually transmitted disease
- More than one sex partner
- Sex at a commercial sex venue
- Sex in association with a large public event in a geographic area where mpox transmission is occurring.
- Sexual partners of individuals with the aforementioned risk factors
- Individuals who anticipate experiencing any of the aforementioned risk factors
